培美曲塞单药一线治疗19例晚期老年非小细胞肺癌的临床观察被引量：2

原文传递

导出

摘要肺癌已成为发病率最高的恶性肿瘤,其死亡率已占癌症死亡率之首,非小细胞性肺癌（NSCLC）约占肺癌的80%。30%发生于70岁以上的患者,老年化趋势比较严重,而且大多数就诊时已到中晚期,失去手术机会,化疗是主要的治疗手段。

作者潘宇凯吴丹刘雄伟赵韬

机构地区江苏省江阴市人民医院肿瘤科

出处《中国肿瘤临床与康复》 2011年第1期86-87,共2页 Chinese Journal of Clinical Oncology and Rehabilitation

关键词老年非小细胞肺癌一线治疗中晚期临床观察培美曲塞非小细胞性肺癌癌症死亡率单药

分类号 R734.2 [医药卫生—肿瘤] R730.53 [医药卫生—肿瘤]

引文网络
相关文献

参考文献7

1李树婷,马飞,孙燕.抗肿瘤代谢新药——培美曲塞[J].癌症进展,2005,3(5):471-476. 被引量：73
2Adjei AA. Pemetrexed(ALIMTA) ,a novel muhitargeted antinecplastic agent[ J ]. Clin Cancer Res ,2004,10 (12) :4276-4280.
3Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-smallcell lung cancer previously treated with chemotherapy [ J ]. J Clin Onco1,2004,22 (9) : 1589-1597.
4Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first - line chemotherapy for patients with advanced non - small - cell lung cancer:A phase II study[J]. J Clin Oneol, 1999,17(4) :1194-1199.
5Clarke SJ, Abratt R, Goedhals L, et al. Phase II trial of pemetrexed disodium ( ALIMTA, LY231514 ) in chemotherapy-narve patients with advanced non - small - cell lung cancer [ J ]. Ann 0ncol,2002,13 (5) :737-741.
6Manegold C, Gatzemeier U, Pawel J, et al. Front-line treatment of advanced non - small - cell lung cancer with MTA ( LY231514 pemetrexed disodium, ALIMTA) and cisplatin : a multicenter phase II trial[J]. Ann Oncol,2000,11 (4) :435-440.
7Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disedium, a muhitargeted antifalate, and cisplatin zo first-line therapy in patients with advanced non-small-cell lung carcinoma:a study of the National Cancer Institute of Canada Clinical Trails Group [ J ]. Cancer,2001,92:595-600.

二级参考文献16

1[1]Calvert H. An overview of folate metabolism: Features relevant to the action and toxicities of antifolate anticancer agents. Semin Oncol, 1999, 26 (2 Suppl 6) :3
2[2]Sierra EE, Goldman ID. Recent advances in the understanding of the mechanism of membrane transport of folates and antifolates.Semin Oncol. 1999, 26 (2 Suppl 6): 11
3[3]Mendelsohn LG, Shih C, Chen VJ, et al. Enzyme inhibition,polyglutamation, and the effect of LY231514 (MTA) on purine biosynthesis. Semin Oncol, 1999, 26 (2 Suppl 6):42
4[4]Calvert H. MTA, a novel multitargeted antifolate, from preclinical to phase Ⅰ and beyond: Summary and conclusions. Semin Oncol, 1999, 26 (2 Suppl 6): 105
5[5]Schultz RM, Chen VJ, Bewley JR, et al. Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Semin Oncol, 1999, 26 (2 Suppl 6) :68
6[6]Calvert AH, Walling JM. Clinical studies with MTA. Br J Cancer, 1998, 78 (Suppl 3) :35
7[7]Newell DR. Clinical pharmacokinetics of antitumor antifolates.Semin Oncol, 1999, 26 (2 Suppl 6):74
8[8]Thodtmann R, Depenbrock H, Dumez H, et al. Clinical and pharmacokinetic phase Ⅰ study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol,1999, 17 (10):3009
9[9]Bajetta E, Celio L, Buzzoni R, et al. Phase Ⅱ study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann Oncol, 2003, 14(10): 1543
10[10]Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase Ⅲstudy of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 2003, 21 (14):2636